3rd Quarter - Report

FIERCE GOVERNMENT RELATIONS for MOMENTA PHARMACEUTICALS, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Risk Evaluation Mitigation Strategies, industry user fees, S.934 - FDA Reauthorization Act of 2017, H.R. 2430-FDA Reauthorization Act of 2017, H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017

Contacted: SENATE

Bills named: S. 934 (115th), S. 974 (115th), H.R. 2212 (115th), H.R. 2430 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.